Stifel Doubles Down on Clearpoint Neuro at $22 — Can a $470M Company Really Capture the Gene-Therapy Delivery Market?
Shares of Clearpoint Neuro surged 11.1% to $15.52 on September 22 after Stifel reiterated its Buy rating and $22 price target, implying another 42% upside from today's close. The call arrived with no new company announcement — just an analyst's conviction that the market is underpricing a small medical-device maker that supplies the surgical tools needed to deliver gene therapies directly into the brain.
A Steady Drumbeat of Bullish Calls, but the Stock Keeps Sliding Back
Stifel initiated coverage on CLPT in May at $16, when shares traded near $11.68.
It raised the target to $22 from $25 in early August after Q2 results.
In the latest note, the firm conceded that updates in the quarterly filing were "somewhat limited" and that disposables revenue was soft. Still, with both covering analysts rating CLPT a "Strong Buy" and an average 12-month target of $23.50 , the gap between Wall Street optimism and the stock's actual trajectory is striking — shares hit a 52-week high of $30.10 before halving.
A Q2 Revenue Miss Hangs Over the Bull Case
Q2 revenue came in at $10.9 million — 18% growth year-over-year but 14% below estimates — while the company posted a loss of $0.38 per share, wider than the expected $0.29.
Management responded by cutting full-year guidance to $48–$52 million , down from the original $52–$56 million range. Cash stood at $35.6 million at the end of Q1 , and operating losses are widening alongside spending on its new preclinical lab and sales force. For a company with roughly 30.5 million shares outstanding , every missed quarter chips away at the runway investors are counting on.
The Gene-Therapy Bet Is Enormous — and Still Mostly Future Revenue
Management targets an additional $300 million in annual revenue from commercial drug delivery alone — treating just 1% of patients in indications under expedited FDA review — creating a pathway to $500 million total.
The first commercial therapies using ClearPoint's tools could win approval as late as late 2026, generating $20,000-plus in disposables per procedure at 80–90% gross margins.
The company already works with over 60 biopharma partners and has 175-plus active global centers.
The Bottom Line for Shareholders Today's pop reflects the market pricing in hope, not new evidence. The real inflection — partner-drug approvals that turn Clearpoint's tools into recurring revenue streams — remains quarters away. Until revenue catches up with the vision, the stock will trade on analyst conviction and headline momentum, both of which can evaporate quickly.